Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin

N/ATerminatedNCT00952055

Winthrop University Hospital152 enrolled

Overview

This is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome (ACS) patients by measuring serum neopterin levels. Serum neopterin is a marker for measuring macrophage activation. Prior studies have illustrated that there are elevated serum neopterin levels in ACS. Patients enrolled are those with ACS. Blood samples are drawn at presentation, and at 72 hours after admission, or at office visits and at 72 hours later. Neopterin levels are measured via a commercially available assay..

The study is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome (ACS) patients by measuring serum neopterin levels. Serum neopterin is a marker for measuring macrophage activation. Prior studies have illustrated that there are elevated serum neopterin levels in ACS. The investigators' study focused on comparing different treatment arms with regard to their neopterin levels and correlating neopterin levels to the Thrombolysis in Myocardial Infarction (TIMI) risk score. Patients enrolled are those with ACS. Blood samples are drawn at presentation, and at 72 hours after admission, or at office visits and at 72 hours later. Neopterin levels are measured via a commercially available assay.

Study Type

OBSERVATIONAL

Enrollment

152

Conditions

Acute Coronary Syndrome

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chest pain and either ST segment elevation or depression \> 0.1 mV in at least 2 contiguous electrocardiographic leads as well as elevation in troponin levels. Exclusion Criteria: * History of medical conditions known to alter neopterin concentrations in blood. The exclusion criteria includes: * renal failure, * history of HIV, * transplant patients, * active infections, * history of autoimmune disease, * malignancy, * phenylketonuria, * immune mediated liver disease, and * patients taking immunomodulating therapy.

Outcomes

Primary Outcomes

Determine if serum neopterin is a useful marker in risk stratifying patients with acute coronary syndromes as it relates to vascular endothelial dysfunction.

Time frame: 8 year study - 2011 anticipated study completion

Secondary Outcomes

Evaluate whether serum neopterin is a useful marker in a similar manner as LPGD-S.

Time frame: 5 years